Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 1989 Oct;160(4):700–705. doi: 10.1093/infdis/160.4.700

Ineffectiveness of Recombinant Interferon-βserine Nasal Drops for Prophylaxis of Natural Colds

Steven J Sperber 1,2,*, Paul A Levine 1,2, James V Sorrentino 1,2, Donald K Riker 1,2, Frederick G Hayden 1,2,1
PMCID: PMC7109997  PMID: 2551976

Abstract

Two randomized, double-blind, placebo-controlled trials during early autumn of 1986 and 1987 evaluated the efficacy and tolerance of recombinant interferon-βserine (rIFN-βser) nasal drops for prevention of natural rhinovirus colds. In 1986, 9 × 106 units of rIFN-βser (139 subjects) or placebo (157) were adminstered once daily except Sundays for 4 w. Rhinovirus colds occurred in 2.8% of rIFN-βser recipients and 6.0% of placebo recipients during the treatment period (52% reduction, P = .3). In 1987, 24 × 106 units of rIFN-βser (186) or placebo (197) were given daily for 25 consecutive days. Rhinovirus colds developed in 6.3% of rIFN-βser recipients and 5.3% of placebo recipients. In each study, illness frequency and number of days with subjective colds did not differ between the groups. Recipients of nasal drops of rIFN-βser at either dosage did not differ in tolerance from placebo recipients. The lack of both prophylactic efficacy and nasal toxicity are in contrast to prior observations with nasal sprays of rIFN-α2b.


Articles from The Journal of Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES